Rheumatoid arthritis (RA) is a long-lasting intractable autoimmune disorder, which has become a substantial public health problem. Despite widespread use of biologic drugs, there have been uncertainties in efficacy and long-term safety. Mesenchymal stem cells (MSCs) have been suggested as a promising alternative for the treatment of RA because of their immunomodulatory properties. However, the precise mechanisms of MSCs on RA-related immune cells are not fully elucidated. The aim of this study was to investigate the therapeutic potential of human umbilical cord blood-derived MSCs (hUCB-MSCs) as a new therapeutic strategy for patients with RA and to explore the mechanisms underlying hUCB-MSC-mediated immunomodulation. Mice with collagen-induced arthritis (CIA) were administered with hUCB-MSCs after the onset of disease, and therapeutic efficacy was assessed. Systemic delivery of hUCB-MSCs significantly ameliorated the severity of CIA to a similar extent observed in the etanercept-treated group. hUCB-MSCs exerted this therapeutic effect by regulating macrophage function. To verify the regulatory effects of hUCB-MSCs on macrophages, macrophages were co-cultured with hUCB-MSCs. The tumor necrosis factor (TNF)-α-mediated activation of cyclooxygenase-2 and TNF-stimulated gene/protein 6 in hUCB-MSCs polarized naive macrophages toward an M2 phenotype. In addition, hUCB-MSCs down-regulated the activation of nucleotide-binding domain and leucine-rich repeat pyrin 3 inflammasome via a paracrine loop of interleukin-1β signaling. These immune-balancing effects of hUCB-MSCs were reproducible in co-culture experiments using peripheral blood mononuclear cells from patients with active RA. hUCB-MSCs can simultaneously regulate multiple cytokine pathways in response to pro-inflammatory cytokines elevated in RA microenvironment, suggesting that treatment with hUCB-MSCs could be an attractive candidate for patients with treatment-refractory RA.

To determine whether glucocorticoids (GCs) play a role in regulating uterine function in cow, the present study examined the expression of mRNA encoding GC receptor (GC-R) a, 11b-hydroxysteroid dehydrogenase (11-HSD) type 1 and type 2, and the activity of 11-HSD1 in bovine endometrial tissue throughout the estrous cycle. We also studied the effects of cortisol on basal, oxytocin (OT)-and tumor necrosis factor-a (TNFa)-stimulated prostaglandin (PG) production. A quantitative real-time PCR analysis revealed that GC-Ra mRNA was expressed more strongly in the mid-luteal stage (days 8-12) than in the other stages. In contrast to GC-Ra mRNA expression, 11-HSD1 mRNA expression was greater in the follicular stage than in the other stages, whereas 11-HSD2 mRNA expression was lowest in the follicular stage. The activity of 11-HSD1 was greater in the follicular stage and estrus than in the other stages and was lowest in the mid-luteal stage. Cortisone was dosedependently converted to cortisol in the cultured endometrial tissue. Although cortisol did not affect either the basal or OT-stimulated production of PGs in the cultured epithelial cells, the production of PGs stimulated by TNFa in the stromal cells was suppressed by cortisol (P!0 . 05). Cortisol suppressed basal prostaglandin (PG)F2a without affecting basal PGE2 production in the stromal cells. The overall results suggest that the level of cortisol is locally regulated in bovine endometrium throughout the estrous cycle by 11-HSD1, and that cortisol could act as a luteoprotective factor by selectively suppressing luteolytic PGF2a production in bovine endometrium.

Interleukin-1 (IL1) has been shown to be a potent stimulator of prostaglandin (PG) production in bovine endometrium. The aim of the present study was to determine the cell types in the endometrium (epithelial or stromal cells) responsible for the secretion of PGE2 and PGF2a in response to IL1A, and the intracellular mechanisms of IL1A action. Cultured bovine epithelial and stromal cells were exposed to IL1A or IL1B (0 . 006-3 . 0 nM) for 24 h. IL1A and IL1B dose-dependently stimulated PGE2 and PGF2a production in the stromal cells, but not in the epithelial cells. The stimulatory effect of IL1A (0 . 06-3 . 0 nM) on PG production was greater than that of IL1B.The stimulatory actions of IL1A on PG production was augmented by supplementing arachidonic acid (AA). When the stromal cells were incubated with IL1A and inhibitors of phospholipase (PL) C or PLA2 (1 mM; anthranilic acid), only PLA2 inhibitor completely stopped the stimulatory action of IL1A on PG production. Moreover, a specific cyclooxygenase-2 (COX2) inhibitor blocked the stimulatory effect of IL1A on PG production. IL1A (0 . 06 nM) promoted COX2 and microsomal PGE synthase-1 (PGES1) gene and its protein expression. The expression of COX1, PGES2, PGES3, and PGF synthase (PGFS) mRNA was not affected by IL1A in the stromal cells. The overall results indicate that 1) the target of IL1A and IL1B for stimulating both PGE2 and PGF2a production is the stromal cells, 2) IL1A is a far more potent stimulator than IL1B on PG production in stromal cells, 3) the stimulatory effect of IL1A on PG production is mediated via the activation of PLA2 and COX2, and (4) IL1A induced PG production by increasing expressions of COX2 and PGES1 mRNAs and their proteins in bovine stromal cells.

Abstract. Vascular endothelial growth factor (VEGF) is a well known angiogenic factor that has been suggested to play some physiological roles in reproductive organs. To clarify whether VEGF is involved in regulating bovine endometrial function locally, in experiment 1, we determined the expression of VEGF, VEGF receptor (VEGFR) 1 and VEGFR2 throughout the estrous cycle in endometrial tissues. Endometrial tissue was collected at estrus (Day 0), the early I (Days 2-3), early II (Days 5-6), mid and late luteal stages and the follicular stage . RT-PCR and Western blotting analysis revealed that VEGF mRNA expression at estrus was higher than at the early I, early II and late luteal stages (P<0.05), whereas VEGF protein content was greatest at the early I luteal stage and decreased thereafter. VEGFR1 mRNA expression was lower at estrus and at the early I and early II luteal stages than at the other stages, whereas VEGFR1 protein expression did not change significantly throughout the estrous cycle (P<0.05). VEGFR2 mRNA expression was higher at the mid and late luteal stages than at the early I and early II luteal stages, and VEGFR2 protein was higher at the mid and late luteal stages than at estrus (P<0.05). In experiment 2, to determine the effect of VEGF on prostaglandin (PG) F2α and PGE2 production by endometrial cells, cultured endometrial epithelial and stromal cells were exposed to VEGF (0, 5, 50, 100 and 200 ng/ml) for 24 h. VEGF (200 ng/ml) stimulated PGF2α production by stromal cells (P<0.05), but not PGE2 production. VEGF did not affect PG production by endometrial epithelial cells. The overall results suggest that VEGF and its receptors are regulated throughout the estrous cycle and that VEGF participates in the local regulation of bovine endometrial function by a selective modulation of PGF2α production in stromal cells in an auto-and/or paracrine manner. Key words: Bovine, Endometrium, Estrous cycle, VEGF, VEGF receptors (J. Reprod. Dev. 56: [223][224][225][226][227][228][229] 2010) ascular endothelial growth factor (VEGF) is a well known angiogenic factor that plays important physiological roles in a wide range of cells and tissues [1]. In reproductive organs, VEGF is required for normal ovarian angiogenesis and growth of the endometrium throughout the ovulatory cycle in humans [2,3] and rodents [4,5]. In addition, the vascular hyperpermeability induced by VEGF seems to be essential for normal implantation in rodents [6]. The above findings suggest that VEGF has pivotal roles in regulating the functions of the cyclic and pregnant endometrium. In cows, VEGF expression has been observed in the ovary [7,8] The biological actions of VEGF are mediated by two types of tyrosine kinase receptors, VEGFR1 (Flt-1) and VEGFR2 (Flk-1/ KDR) [1,11]. VEGFR1 has a high affinity for VEGF, and its signal for angiogenesis is weak [12]. Although VEGFR1 mediates an essential signal for normal vascularization, it seems that VEGFR1 does not mediate stimulation of endothelial cell proliferation [13]. The exact function of ...

No abstract